Galapagos NV

80.99-1.45-1.76%Vol 42.05K1Y Perf -61.34%
Apr 23rd, 2021 10:38 DELAYED
BID80.85 ASK80.94
Open81.38 Previous Close82.44
Pre-Market81.35 After-Market-
 -1.09 -1.32%  - -
Target Price
95.50 
Analyst Rating
Moderate Buy 2.31
Potential %
18.11 
Finscreener Ranking
★★★★+ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     58.58
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     60.14
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap5.31B 
Earnings Rating
Neutral
Price Range Ratio 52W %
4.08 
Earnings Date
6th May 2021

Today's Price Range

80.8381.67

52W Range

74.51233.14

5 Year PE Ratio Range

-139.0098.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
4.16%
1 Month
4.39%
3 Months
-25.86%
6 Months
-35.42%
1 Year
-61.34%
3 Years
-14.18%
5 Years
80.99%
10 Years
507.96%

TickerPriceChg.Chg.%
GLPG80.99-1.4500-1.76
AAPL133.581.64001.24
GOOG2 293.0525.13001.11
MSFT259.091.92000.75
XOM55.750.48000.87
WFC43.560.86002.01
JNJ165.440.26000.16
FB298.451.93000.65
GE13.580.17001.27
JPM149.552.18001.48
ValuationValueIndustryS&P 500US Markets
-14.30
1.63
10.95
2.10
-9.70
-7.87
1.65
48.85
-987 840 000.00
Forward PE-16.62
PEG16.87
Financial StrengthValueIndustryS&P 500US Markets
8.40
8.50
0.01
0.01
-32.00
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
16.00
-65.60
-61.80
-21.20
-67.08
RevenueValueIndustryS&P 500US Markets
471.49M
7.20
64.17
74.75
Earnings HistoryEstimateReportedSurprise %
Q03 2020-1.23-1.46-18.70
Q02 2020-1.07-1.95-82.24
Q01 2020-0.95-0.869.47
Q04 2019--1.68-
Q03 2019-1.418.72718.44
Q02 2019-0.84-0.97-15.48
Q01 2019-1.19-1.0115.13
Q04 2018-0.34-
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.713.39Positive
6/2021 QR-1.6812.04Positive
12/2021 FY-5.0917.77Positive
12/2022 FY-4.7635.85Positive
Next Report Date6th May 2021
Estimated EPS Next Report-1.71
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume42.05K
Shares Outstanding65.51M
Trades Count666
Dollar Volume20.74M
Avg. Volume299.27K
Avg. Weekly Volume170.46K
Avg. Monthly Volume289.32K
Avg. Quarterly Volume315.53K

Galapagos NV (NASDAQ: GLPG) stock closed at 82.44 per share at the end of the most recent trading day (a -0.84% change compared to the prior day closing price) with a volume of 123.08K shares and market capitalization of 5.31B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1407 people. Galapagos NV CEO is Onno van de Stolpe.

The one-year performance of Galapagos NV stock is -61.34%, while year-to-date (YTD) performance is -16.71%. GLPG stock has a five-year performance of 80.99%. Its 52-week range is between 74.51 and 233.14, which gives GLPG stock a 52-week price range ratio of 4.08%

Galapagos NV currently has a PE ratio of -14.30, a price-to-book (PB) ratio of 1.63, a price-to-sale (PS) ratio of 10.95, a price to cashflow ratio of 2.10, a PEG ratio of 2.32, a ROA of -5.18%, a ROC of -12.08% and a ROE of -11.01%. The company’s profit margin is -67.08%, its EBITDA margin is -61.80%, and its revenue ttm is $471.49 Million , which makes it $7.20 revenue per share.

Of the last four earnings reports from Galapagos NV, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.71 for the next earnings report. Galapagos NV’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Galapagos NV is Moderate Buy (2.31), with a target price of $95.5, which is +18.11% compared to the current price. The earnings rating for Galapagos NV stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Galapagos NV has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Galapagos NV has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.12, ATR14 : 2.86, CCI20 : 168.59, Chaikin Money Flow : 0.13, MACD : -3.31, Money Flow Index : 45.30, ROC : 4.51, RSI : 51.09, STOCH (14,3) : 90.15, STOCH RSI : 0.84, UO : 61.10, Williams %R : -9.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Galapagos NV in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (38.46 %)
5 (38.46 %)
4 (30.77 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
7 (53.85 %)
7 (53.85 %)
7 (53.85 %)
Moderate Sell
1 (7.69 %)
1 (7.69 %)
1 (7.69 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (7.69 %)
Summary RatingModerate Buy
2.31
Moderate Buy
2.31
Hold
2.62

Galapagos NV

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

CEO: Onno van de Stolpe

Telephone: +32 15342900

Address: Generaal De Wittelaan L11 A3, Mechelen 2800, , BE

Number of employees: 1 407

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

Bearish Bullish

52%48%

News

Stocktwits